2025-11-30 - Analysis Report
Okay, here's a breakdown of the provided data for Merck & Co. Inc. (MRK), with simple numbers first, followed by analysis.

**0) Report in English**

**1) Return Rate Comparison**

*   Ticker: MRK
*   Company: Merck & Co Inc
*   Overview: A global pharmaceutical company focused on developing innovative medicines and vaccines.
*   MRK Cumulative Return: 23.86%
*   VOO (S&P 500) Cumulative Return: 101.92%
*   Divergence:
    *   Current: -79.1
    *   Relative Divergence: 19.7

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD     | Alpha   | Beta    | Cap(B) |
|------------|---------|---------|---------|---------|--------|
| 2015-2017  | 1.0%    | 68.5%   | -28.0%  | 0.0     | 134.1  |
| 2016-2018  | 36.0%   | 69.8%   | 21.0%   | -0.0    | 182.1  |
| 2017-2019  | 40.0%   | 69.8%   | 18.0%   | 0.3     | 216.8  |
| 2018-2020  | 16.0%   | 79.6%   | -8.0%   | 0.3     | 195.0  |
| 2019-2021  | 2.0%    | 79.6%   | -44.0%  | 0.7     | 191.4  |
| 2020-2022  | 15.0%   | 79.6%   | 16.0%   | 0.7     | 277.1  |
| 2021-2023  | 33.0%   | 79.6%   | 31.0%   | 0.3     | 272.3  |
| 2022-2024  | -4.0%   | 79.6%   | -25.0%  | 0.2     | 248.5  |
| 2023-2025  | -25.0%  | 71.5%   | -92.0%  | 1.8     | 261.8  |

**Analysis:**

*   **Underperformance:** MRK has significantly underperformed the S&P 500 (VOO) over the data period.  The current divergence is a substantial -79.1, indicating a large gap in cumulative returns. The relative divergence of 19.7 suggests that the current divergence is closer to its historical minimum than maximum.
*   **Alpha and Beta:** Alpha has been volatile, with significantly negative number. Beta values are generally low, suggesting MRK's price is not strongly correlated with the broader market movements.
*   **CAGR and MDD:**  CAGR (Compound Annual Growth Rate) has fluctuated.  MDD (Maximum Drawdown) values are high, indicating substantial potential for losses during downturns.

**2) Recent Stock Price Fluctuations**

*   Close: 104.83
*   Last Market:
    *   Price: 104.83
    *   Previous Close: 104.63
    *   Change: 0.19
*   5-day SMA: 102.66
*   20-day SMA: 92.84
*   60-day SMA: 87.33

**Analysis:**

*   The stock price is currently above all three moving averages (5, 20, and 60-day).  This suggests a recent upward trend. The 5-day SMA is above the 20-day, which is above the 60-day SMA, further confirming the upward trend.

**3) Indicators**

*   MRI: 0.9 (Medium Investment Recommended)
*   RSI: 89.18 (Overbought)
*   PPO: 1.41
*   Hybrid Signal: Buy 100% of cash (11 shares - Very Safe - MRI:0.90)
*   Recent Divergence Change: 7.5 (short-term rise)
*   Expected Return: -36.3%

**Analysis:**

*   **MRI:** The Market Risk Indicator suggests a "Medium Investment" recommendation.
*   **RSI:** The high RSI indicates that the stock is overbought, meaning it may be due for a pullback or correction.
*   **PPO:** Positive PPO suggests a short-term bullish trend.
*   **Hybrid Signal:**  The hybrid signal recommends buying. This seems to contradict the RSI and Expected Return findings, suggesting mixed signals.
*   **Recent Divergence Change:**  The recent increase in relative divergence confirms the short-term upward price movement.
*   **Expected Return:**  A negative expected return of -36.3% is a significant concern, suggesting that long-term investment at this point might be unfavorable compared to the S&P 500.

**4) Recent News & Significant Events**

*   **Why Is Merck Stock Surging?** (Forbes) - Positive sentiment
*   **Why Merck (MRK) Stock Is Trading Up Today** (Yahoo Finance) - Positive sentiment
*   **A Look at Merck's (MRK) Valuation as Shares Gain Momentum** (simplywall.st) - Valuation focus
*   **3 Non-AI Stocks to Buy: MRK, UPS, CVX** (The Motley Fool) - Positive sentiment, buy recommendation
*   **Why Merck Stock Jumped 40%** (Trefis) - Significant price increase
*   **Mackenzie Financial Corp Has $84.18 Million Stock Position in Merck & Co., Inc.** (MarketBeat) - Institutional investment

**Analysis:**

*   Recent news is overwhelmingly positive, with multiple articles highlighting a surge in the stock price and potential reasons for the increase. Articles cite a positive valuation for the stock, as well as highlight some external companies recommending to buy the stock.

**4-2) Analyst Opinions**

*   Consensus: Buy (~1.97 on a 1-5 scale)
*   Number of Opinions: 26
*   Target Price:
    *   Average: $104.27
    *   High: $139.00
    *   Low: $82.00
*   Recent Rating Changes: Not Available.

**Analysis:**

*   The analyst consensus is generally positive, with a "Buy" recommendation.  The average target price is around the current price.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-11-05 | 2.32 | 17.28 B$ |
| 2025-08-05 | 1.76 | 15.81 B$ |
| 2025-05-02 | 2.01 | 15.53 B$ |
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2025-11-05 | 1.25 | 16.66 B$ |

**Analysis:**

*   Earnings per share (EPS) and Revenue have fluctuated over the past few quarters, with no clear upward or downward trend. The most recent quarter (2025-11-05) shows a large increase in EPS.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
|--------------|-------------|---------------|
| 2025-09-30   | $17.28B     | 77.69%        |
| 2025-06-30   | $15.81B     | 77.50%        |
| 2025-03-31   | $15.53B     | 77.98%        |
| 2024-12-31   | $15.62B     | 75.50%        |
| 2024-09-30   | $16.66B     | 75.51%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE   |
|--------------|-------------|-------|
| 2025-09-30   | $51.85B     | 11.16%|
| 2025-06-30   | $48.99B     | 9.04% |
| 2025-03-31   | $48.34B     | 10.51%|
| 2024-12-31   | $46.31B     | 8.08% |
| 2024-09-30   | $44.50B     | 7.09% |

**Analysis:**

*   **Revenue:** Revenue shows volatility, with no obvious upward or downward trend.
*   **Profit Margin:** Profit margins are relatively high and stable, showing a good management of their profitability from the raw revenue.
*   **Equity:** Equity has been generally increasing, indicating growth in the company's net worth.
*   **ROE:** Return on Equity has fluctuated, indicating volatile profitability of equity investments.

**7) Comprehensive Analysis**

MRK has significantly underperformed the S&P 500 in cumulative return over the provided historical period. The Alpha and Beta analysis reveals volatile Alpha, suggesting inconsistent performance relative to the market. The recent price action shows an upward trend, reflected in the stock price being above its moving averages. This is supported by positive news headlines and a "Buy" consensus from analysts. The hybrid signal, while positive, conflicts with the high RSI, which suggests the stock is overbought. The negative expected return is a major concern. Overall, the data presents a mixed picture. While there's positive short-term momentum, there are also indicators of overvaluation and potential for a correction. Long-term, the underperformance compared to the S&P 500 and negative expected return raise concerns.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.